Hamid Emamekhoo, ASCO 2019 – CheckMate 920 study
At the ASCO 2019 annual meeting, Hamid Emamekhoo discusses the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases (CheckMate 204) and how these findings will likely impact the management of the disease.
Questions
1. What are the limitations of current treatment options for patients with metastatic renal cell carcinoma (mRCC) brain metastases? (0:03)
2. What were the findings of CheckMate 920 in patients with mRCC brain metastases? (0:37)
3. What was the anti-tumour activity of ipilimumab plus nivolumab in these patients? (3:11)
4. How are these findings likely to impact on the clinical management of mRCC brain metastases? (4:01)
Speaker disclosure: Hamid Emamekhoo has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
